- Home
- ACRV vs BCAB Comparison
ACRV vs BCAB Comparison
Compare ACRV & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRV | BCAB |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 71.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACRV | BCAB |
|---|---|---|
| Price | $2.49 | $0.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $14.67 | $1.00 |
| AVG Volume (30 Days) | 602.2K | ★ 2.1M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $805.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.24 |
| 52 Week High | $8.00 | $1.72 |
Technical Indicators
Market Signals| Indicator | ACRV | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.87 | 48.78 |
| Support Level | $2.16 | $0.79 |
| Resistance Level | $2.55 | $0.90 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 74.83 | 14.41 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.